The US FDA approves an anti-aging therapeutic indicated specifically to slow biological aging before 2035.

Question

Six frontier AI models put this at 10% by 17 Sept 2036. Full reasoning from every model.

WillHappen.ai · Accepted Answer

10% — the median of 6 frontier models, resolving by 2036-09-17.

Answer

Gemini (Google): 12% — FDA approval requires treating aging as a primary indication, but validated surrogate biomarkers lack regulatory acceptance. The FDA does not recognize natural aging as an ICD disease, requiring a multi-year paradigm shift and formal biomarker qualification. Candidate trials like TAME rely on composite disease delays rather than an explicit aging label and face severe funding delays. FDA formal guidance establishing epigenetic or physiological clocks as valid surrogate endpoints would rapidly double these odds.

Answer

Claude (Anthropic): 11% — Hinges on FDA accepting aging itself as a treatable indication, not just a disease proxy, by 2036. FDA has never approved a drug indicated for 'aging' itself; TAME trial for metformin only targets age-related disease endpoints, not an aging label. Regulatory pathway would require new biomarker-based endpoints (e.g., biological age clocks) validated as surrogate endpoints, which regulators have been slow to accept. A decade is meaningful time and rapamycin/metformin/senolytic trials could shift FDA thinking, but institutional caution and lack of a fully validated aging biomarker…

Answer

GPT (OpenAI): 9% — This hinges on FDA accepting a validated aging surrogate and a sponsor running a pivotal program for that label. FDA approvals require a defined indication and substantial evidence; no drug is currently approved to treat aging itself. By 2035, biomarkers such as epigenetic clocks may mature, but FDA has not established them as approval endpoints for slowing aging. Odds rise sharply if FDA issues aging-specific endpoint guidance or accepts a longevity biomarker in a registrational trial before 2030.

Answer

Grok (xAI): 18% — FDA must treat aging itself as an approvable indication after a completed pivotal trial. A sponsor needs Phase-3 data in hand by ~2032 for any 2034 NDA; no aging-specific trial is that advanced today. Zero FDA precedents exist for an aging indication; TAME and similar efforts have stalled for a decade. Published FDA guidance on aging endpoints or a positive TAME-style readout would move the odds most.

Answer

DeepSeek (DeepSeek): 6% — This turns on whether the FDA creates a validated aging indication, which no sponsor has yet forced it to do. The FDA has never approved any drug for aging itself; the closest precedent is the 2023-2024 dog-aging trials (LOY-001, rapamycin) which are not human pathways. The FDA has no validated aging endpoint; sponsors would need a disease-specific indication like frailty or sarcopenia, which is not the same as an anti-aging label. TAME (metformin) has been discussed since 2015 and still lacks funding and an agreed primary endpoint, showing how slowly this field moves.

Answer

Qwen (Alibaba): 3% — FDA has never recognized aging as a disease; no regulatory pathway exists for a

The US FDA approves an anti-aging therapeutic indicated specifically to slow biological aging before 2035.

A fully lab-grown solid organ is successfully transplanted into a human patient in a clinical trial before 2032.

The US FDA approves a gene therapy targeting sensorineural hearing loss before 2030.

A gene editing therapy for herpes simplex virus enters Phase 3 clinical trials before 2029.

The US FDA approves an in vivo CRISPR gene editing therapy before January 1, 2028.